To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in the SOW as well as other rapidly emerging viruses that utilize the same…
Ended Awarded Last action
- Contract number
- 75N93022F00003
- Awardee
-
Utah State University UEI SPE2YDWHDYU4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $294,070
Award facts
- Opportunity
-
- B12 Solicitation number
- Contract value 63% obligated
-
- $294,070.00 Current, with exercised options
- $466,684.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Logan, UT 84322, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $466,684.00 firm fixed price delivery order to Utah State University (USU) to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in the statement of work, as well as other rapidly emerging viruses using the same assay methodology. This delivery order is part of the In Vitro Assessments of Antimicrobial Activity (IVAAA) indefinite delivery, indefinite quantity (IDIQ) contract. USU is a public research university and 1862 land-grant institution located in Logan, Utah that has experience conducting research and testing related to viruses, animal health, and aerospace technologies for federal agencies. No set-aside designation was used for this award.
Description
To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in the SOW as well as other rapidly emerging viruses that utilize the same assay methodology.
Quick answers
Who was awarded contract 75N93022F00003?
75N93022F00003 was awarded to Utah State University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 29, 2022.
How much is contract 75N93022F00003 worth?
The government has obligated $294,070 on 75N93022F00003. Its potential value, with all options, is $466,684.
Is contract 75N93022F00003 an order under another contract?
Yes. 75N93022F00003 is a delivery order under 75N93019D00021, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93022F00003 competed?
The extent of competition for 75N93022F00003 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award